Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 20/20 | 1.00 |
| ▸ | PGR | P06401 | 3/20 | 1.00 |
| ▸ | NR3C2 | P08235 | 3/20 | 1.00 |
| ▸ | AR | P10275 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30335364 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR3C2AR | |
| SCHEMBL6077179 | 0.91 | NR3C1 (0.83) | NR3C1PGRNR3C2AR | |
| SCHEMBL6076827 | 0.87 | NR3C1 (0.78) | NR3C1PGRNR3C2AR | |
| SCHEMBL14602512 | 0.87 | NR3C1 (0.78) | NR3C1PGRNR3C2AR | |
| SCHEMBL24252000 | 0.86 | NR3C1 (0.76) | NR3C1PGRNR3C2AR | |
| SCHEMBL5644055 | 0.85 | NR3C1 (0.74) | NR3C1PGRNR3C2AR | |
| SCHEMBL5641166 | 0.85 | NR3C1 (0.74) | NR3C1PGRNR3C2AR | |
| SCHEMBL5642432 | 0.84 | NR3C1 (0.73) | NR3C1PGRNR3C2AR | |
| SCHEMBL4621610 | 0.84 | NR3C1 (0.73) | NR3C1PGRNR3C2AR | |
| SCHEMBL4622412 | 0.84 | NR3C1 (0.73) | NR3C1PGRNR3C2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725558-A2 | IMMUNOABLATIVE THERAPIES | AVM Biotechnology, LLC (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-3860612-B1 | IMMUNOABLATIVE THERAPIES | AVM BIOTECHNOLOGY LLC (US) | 2026-03-04 | — | — | EP | disclosed |
| EP-3768324-B1 | METHODS FOR MODULATING INNATE LYMPHOID CELL ACTIVITY, ANTIBODY DRUG CONJUGATES AND USES IN THERAPY | INST NAT SANTE RECH MED (FR) | 2025-11-26 | — | — | EP | disclosed |
| US-12048705-B2 | Immunoablative therapies | AVM BIOTECHNOLOGY, LLC (US) | 2024-07-30 | — | — | US | disclosed |
| EP-3632446-B3 | IMMUNOABLATIVE THERAPIES | AVM BIOTECHNOLOGY LLC (US) | 2024-01-24 | — | — | EP | disclosed |
| EP-3490605-B1 | REPLACEMENT OF CYTOTOXIC PRECONDITIONING BEFORE CELLULAR IMMUNOTHERAPY | AVM BIOTECHNOLOGY LLC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-11446314-B2 | Immunoablative therapies | AVM BIOTECHNOLOGY, LLC (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220160729-A1 | Replacement of Cytotoxic Preconditioning Before Cellular Immunotherapy | AVM BIOTECHNOLOGY, LLC (US) | 2022-05-26 | — | — | US | disclosed |
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | ST. ANNA KINDERKREBSFORSCHUNG (AT) | 2022-02-10 | — | — | US | disclosed |
| US-11219628-B2 | Replacement of cytotoxic preconditioning before cellular immunotherapy | AVM BIOTECHNOLOGY, LLC (US) | 2022-01-11 | — | — | US | disclosed |
| US-20200108078-A1 | IMMUNOABLATIVE THERAPIES | AVM BIOTECHNOLOGY, LLC | 2020-04-09 | — | — | US | disclosed |
| EP-3632460-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | St. Anna Kinderkrebsforschung (AT) | 2020-04-08 | — | — | EP | disclosed |
| EP-3632461-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | St. Anna Kinderkrebsforschung (AT) | 2020-04-08 | — | — | EP | disclosed |
| EP-3632446-A1 | IMMUNOABLATIVE THERAPIES | AVM Biotechnology, LLC (US) | 2020-04-08 | — | — | EP | disclosed |
| EP-3490605-A1 | REPLACEMENT OF CYTOTOXIC PRECONDITIONING BEFORE CELLULAR IMMUNOTHERAPY | AVM Biotechnology, LLC (US) | 2019-06-05 | — | — | EP | disclosed |
| EP-3488851-A1 | IMMUNOABLATIVE THERAPIES | AVM Biotechnology, LLC (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20180296572-A1 | REPLACEMENT OF CYTOTOXIC PRECONDITIONING BEFORE CELLULAR IMMUNOTHERAPY | AVM BIOTECHNOLOGY, LLC (US) | 2018-10-18 | — | — | US | disclosed |
| WO-2018183927-A1 | REPLACEMENT OF CYTOTOXIC PRECONDITIONING BEFORE CELLULAR IMMUNOTHERAPY | AVM BIOTECHNOLOGY, LLC (US) | 2018-10-04 | — | — | WO | disclosed |
| US-20150250873-A1 | COMBINATION THERAPY OF ANTI-MIF ANTIBODIES AND GLUCOCORTICOIDS | Baxalta GmbH (CH) | 2015-09-10 | — | — | US | disclosed |
| US-9126997-B1 | Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma | NORTHWESTERN UNIVERSITY (US) | 2015-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150250873-A1 | COMBINATION THERAPY OF ANTI-MIF ANTIBODIES AND GLUCOCORTICOIDS | MIF, NR3C2, NR3C1 | NR3C1 3/4885PGR 117/4885NR3C2 2/4885 |
| US-20220041687-A1 | A GROUP OF CHIMERIC ANTIGEN RECEPTORS (CARS) | CARS1, CD74, HAVCR2 | NR3C1 2873/4885PGR 4023/4885NR3C2 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.